Gainers

• Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out yesterday.
• Evommune (NYSE:EVMN) shares moved upwards by 30.23% to $6.72. The market value of their outstanding shares is at $187.2 million.
• Genmab (NASDAQ:GMAB) stock increased by 28.78% to $57.53. The company's market cap stands at $27.8 billion.
• Axogen (NASDAQ:AXGN) shares rose 28.59% to $48.17. The company's market cap stands at $2.1 billion. As per the news, the Q3 earnings report came out today.
• OrthoPediatrics (NASDAQ:KIDS) shares rose 26.07% to $30.03. The market value of their outstanding shares is at $621.9 million. As per the press release, Q3 earnings came out yesterday.
• Pacific Biosciences (NASDAQ:PACB) shares increased by 23.87% to $3.04. The company's market cap stands at $761.5 million.

Losers

• Bicara Therapeutics (NASDAQ:BCAX) shares fell 43.4% to $9.89 during Wednesday's regular session. The company's market cap stands at $1.1 billion.
• Inhibrx Biosciences (NASDAQ:INBX) shares fell 23.76% to $72.94. The company's market cap stands at $1.4 billion.
• SELLAS Life Sciences Gr (NASDAQ:SLS) shares fell 17.55% to $10.04. The market value of their outstanding shares is at $2.4 billion.
• Tessera Defense (AMEX:HLSQ) stock declined by 16.99% to $0.17. The market value of their outstanding shares is at $4.2 million.
• Rapport Therapeutics (NASDAQ:RAPP) stock decreased by 16.44% to $23.02. The company's market cap stands at $1.3 billion.
• Beta Bionics (NASDAQ:BBNX) shares fell 16.04% to $17.96. The company's market cap stands at $1.1 billion. The company's, Q3 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.